Large Compounders’ Reporting Requirements Would Move Closer To Manufacturers’ In Senate Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Compounding manufacturers would have to report adverse events and quality problems much like traditional drug and biologic makers as a Senate committee moves toward mark up of legislation.
You may also be interested in...
Compounding: How Does FDA Expand Oversight Without Legislation?
After House Republicans indicate legislation expanding agency’s oversight of compounding is unlikely, FDA could consider other regulatory options, like changing internal policies or hoping a court clarifies its regulatory authority.
FDA Compounder Inspections May Help Set New Enforcement Standard
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.